Evidence map›Paper›PMID 41203598›Full record

ArticleCell death & disease2025

The RNA N

Yanhong Tan, Changli Zhou, Sicheng Bian, Huiqin Bian, Yanan Ren, Wencke Walter, Jiuxia Pang, Tao Cheng, Hongwei Wang, Yuchao Yang and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell death & disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Yanhong Tan *Department of Medicine, The MetroHealth System, Case Western Reserve University, Cleveland, OH, USA.
Changli Zhou *Department of Medicine, The MetroHealth System, Case Western Reserve University, Cleveland, OH, USA.
Sicheng BianDepartment of Medicine, The MetroHealth System, Case Western Reserve University, Cleveland, OH, USA.
Huiqin BianDepartment of Medicine, The MetroHealth System, Case Western Reserve University, Cleveland, OH, USA.
Yanan RenRobert H. Lurie Medical Research Center, Chicago, IL, USA.
Wencke WalterMLL Munich Leukemia Laboratory, Munich, Germany.
Jiuxia PangDepartment of Medicine, The MetroHealth System, Case Western Reserve University, Cleveland, OH, USA.
Tao ChengDepartment of Medicine, The MetroHealth System, Case Western Reserve University, Cleveland, OH, USA.
Hongwei WangDepartment of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China.
Yuchao YangDepartment of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China.
Wenzheng GuoDepartment of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China.ORCID http://orcid.org/0009-0005-4210-0258
Lingli ZhangDepartment of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China.
Aref Al-KaliDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
Mark R LitzowDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
Xiaonan HanDepartment of Medicine, The MetroHealth System, Case Western Reserve University, Cleveland, OH, USA.
Jianhua YuDivision of Hematology & Oncology, Department of Medicine, School of Medicine, Chao Family Comprehensive Cancer Center, University of California, Orange, California, USA.
Rendong YangRobert H. Lurie Medical Research Center, Chicago, IL, USA.ORCID http://orcid.org/0000-0002-9512-2240
Gang HuangDepartment of Cell Systems and Anatomy, UT Health San Antonio, Joe R. and Teresa Lozano Long School of Medicine, San Antonio, Texas, USA.
Gregor HoermannMLL Munich Leukemia Laboratory, Munich, Germany.
William TseDepartment of Medicine, The MetroHealth System, Case Western Reserve University, Cleveland, OH, USA.
Shujun LiuDepartment of Medicine, The MetroHealth System, Case Western Reserve University, Cleveland, OH, USA. shujun.liu2@case.edu.

Funding

The Role of HIF1A-DNMT3A axis in AML1/ETO-Driven Acute MyelogenousLeukemiaR01CA248019 · NCI · UNIVERSITY OF MINNESOTA · PI LIU, SHUJUN · 2021 to 2025
$3.2M
Role of an Aberrant N6-Methyladenosine-LncRNA Axis in the Development and Maintenance of Drug Resistance through Regulating the Leukemia Stem CellR01CA266256 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI HUANG, GANG, LIU, SHUJUN · 2022 to 2025
$3.0M
REGULATION OF NICHE CELL DIFFERENTIATION TO SUSTAIN INTESTINAL STEM CELL REGENERATION AGAINST GUT INFLAMMATIONR01DK123299 · NIDDK · CINCINNATI CHILDRENS HOSP MED CTR · PI HAN, XIAONAN · 2020 to 2023
$1.4M
NCI NIH HHS R01 CA248019NCI NIH HHS R01 CA266256NIDDK NIH HHS R01 DK123299U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R01CA266256U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (National Cancer Institute Division of Cancer Epidemiology and Genetics) R01CA248019
6 · The paper itself

Abstract

Long non-coding RNAs (lncRNAs) and RNA N⁶-methyladenosine (m

Indexed as

AdenosineDrug Resistance, NeoplasmLeukemia, Myelogenous, Chronic, BCR-ABL PositivePhosphatidylinositol 3-KinasesRNA, Long NoncodingAnimalsCell Line, TumorHumansMethylationMiceProtein Kinase InhibitorsSignal TransductionAdenosineN-methyladenosinePhosphatidylinositol 3-KinasesProtein Kinase InhibitorsRNA, Long Noncoding

Identifiers

PMID41203598
PMCPMC12594950

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.